Literature DB >> 3030779

Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla.

P Ernsberger, M P Meeley, J J Mann, D J Reis.   

Abstract

Binding sites labeled by [3H]p-aminoclonidine ([3H]PAC) were characterized in bovine brain membranes prepared from the ventrolateral medulla, the probable site of the antihypertensive action of clonidine and analogs. Comparison was made with [3H]PAC binding to membranes prepared from frontal cortex, which has been studied extensively. Saturation binding isotherms for [3H]PAC were similar in the two regions, although Bmax values were approximately two-fold lower in ventrolateral medulla relative to frontal cortex. Norepinephrine and other phenylethylamines displaced [3H]PAC from a maximum of 70% of the total sites in the ventrolateral medulla. The remaining 30% were norepinephrine-insensitive, non-adrenoceptor sites which displayed high affinity for imidazole compounds. Ligand selectivity differed markedly between ventrolateral medulla and frontal cortex, since some imidazole compounds which potently inhibited [3H]PAC binding in the ventrolateral medulla had no effect in frontal cortex. Imidazole binding sites may mediate, in part, the hypotensive action of clonidine and other imidazole compounds in the ventrolateral medulla. These sites may also participate in the functions of a putative endogenous clonidine-like substance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030779     DOI: 10.1016/0014-2999(87)90125-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  61 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Protection of presynaptic alpha-adrenoceptors against irreversible blockade by phenoxybenzamine: preservation of the modulatory effects of exogenous noradrenaline and yohimbine.

Authors:  N Limberger; T Hölting; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

3.  Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Authors:  Yonghua Zhang; Harold K Kimelberg
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 4.  Clonidine extended-release: in attention-deficit hyperactivity disorder.

Authors:  Jamie D Croxtall
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

5.  [3H]-idazoxan binds with high affinity to two sites on hamster adipocytes: an alpha 2-adrenoceptor and a non-adrenoceptor site.

Authors:  A C MacKinnon; C M Brown; M Spedding; A T Kilpatrick
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Central alpha-2 adrenoceptors are responsible for a clonidine-induced cue in a rat drug discrimination paradigm.

Authors:  S Jordan; H C Jackson; D J Nutt; S L Handley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Modulation by central postsynaptic alpha 2-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats.

Authors:  P García-Vallejo; F Barturen; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

8.  Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from I1- and I2-imidazoline binding sites.

Authors:  G J Molderings; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

9.  Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem.

Authors:  G Bricca; J Zhang; H Greney; M Dontenwill; J Stutzmann; A Belcourt; P Bousquet
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

10.  Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors.

Authors:  J P Hieble; D C Kolpak
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.